- Joined
- Apr 21, 2011
- Messages
- 3,718
- Reaction score
- 9,499
Yeah, dude is just straight up lying to the patient so he can be the one to give (lots and lots) of systemics.You'll be seeing that patient at some point, no doubt
Tale as old as time.
Yeah, dude is just straight up lying to the patient so he can be the one to give (lots and lots) of systemics.You'll be seeing that patient at some point, no doubt
This is likely, indeed.You'll be seeing that patient at some point, no doubt
True, but I would argue that this is where we save the most lives and improve QOL relative to the alternative.The WORST treatment we perform in terms of side effects is H&N radiochemotherapy, so this is likely the lowest hanging fruit.
This is likely, indeed.
But let's be honest: The WORST treatment we perform in terms of side effects is H&N radiochemotherapy, so this is likely the lowest hanging fruit.
Well, he was presented in the tumor board. And didn't like the taste (pun intended!) of the recommendation, which was chemorads, obviously.Everything they've tried in H+N hasn't worked: induction chemo, concurrent chemoradiation + immunotherapy, dose de-escalation. None of those have done anything to improve upon the current standard of care.
This patient who is being mismanaged to the point of malpractice should be presented at a H+N tumor board. There is no justification - ZERO - to do "induction immunotherapy" for what may be a curable malignancy. Shameful.
I love my Med Oncs and they love me. Despite shrinking indications for XRT, I still find that I'm able to have nuanced and meaningful discussions with them. Also, we have regular morning conferences and occasionally the Rad Oncs present didactics on new and expanding indications like SBRT of oligomets.
Outside Med Oncs are a different beast, but that has much to do with the intense regional competition as well as their individual views.
Radoncs should run the tumor boards. We are all pretty smart. We have a little more time to read than they do. It will make you more valuable and visible to admin or your physician co-owners.Must med oncs are not interested in nuance. They have 20-30 patients to see plus the hospital.
From some old French data multiagent chemo alone can provide long term LC in ~13%. The efficacy of IO in HN probably isn't going to move the needle that much. Won't stop them from trying for sure.Well, he was presented in the tumor board. And didn't like the taste (pun intended!) of the recommendation, which was chemorads, obviously.
A patient will always find an oncologist that is willing to do something outside of the guideline or a tumor board's proposal.
Induction chemotherapy does not offer long term remission. There are however some patients out there (it's a minority) that can be probably cured from locally advanced H&N cancer with immunochemotherapy, followed by maintenance immunotherapy without any local treatment. The very same principle likely applies to locally advanced NSCLC and melanoma.
Do I endorse it? No.
Do I like it? No.
Do I have to live with it? Yes.
I assume you’re med onc. These are nice words, thank you. Re: more than enough cancer to go around, rad oncs face falling RT utilization in cancer year after year. “Med onc utilization” is booming. Please keep us in your thoughts, in your prayers, and at the table.I'm sorry that this has been your experience with med oncs. It's certainly not the attitude in our institution, in which tumor boards involve academic and PP docs from all oncologic subspecialties and give RO as much of a seat at the table as MO and SO. Regardless, you can probably expect more collegiality from the newer crops, as by now, docs from all specialties recognize that that it's universally the MDs who get hosed and the bean-counting admins who get paid. Their parasitism aside, there's unfortunately more than enough cancer to go around.
I assume you’re med onc. These are nice words, thank you. Re: more than enough cancer to go around, rad oncs face falling RT utilization in cancer year after year. “Med onc utilization” is booming. Please keep us in your thoughts, in your prayers, and at the table.